Riociguat, which enhances NO pathway through the direct stimulation of soluble guanylate cyclase (sGC), constitutes a valuable novel therapy for PAH, although patients may experience episodes of hypotension (Hambly and Granton, 2015; Keating, 2016). Here, SGCB is linked to pulmonary arterial hypertension.